Meta-analysis shows PPAR agonists reduce pruritus severity in primary biliary cholangitis, suggesting new treatment approaches.
PPAR agonists, notably bezafibrate and seladelpar, reduce pruritus severity in PBC patients with moderate-to-severe symptoms and consistently improve itch-specific outcomes. However, effects on global HRQoL remain uncertain. These findings underscore the incorporation of validated, symptom-focused endpoints in future PBC trials.
No takes yet. Share an insight, caveat, or question.
Martins et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: